Biomarkers /
MECOM
Overview
MDS1 and EVI1 complex locus (MECOM) is a gene that encodes a protein that functions as a transcriptional regulator and oncoprotein. The protein may also have roles in hematopoiesis, apoptosis, development, cell differentiation, and cell proliferation. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
MECOM is altered in 3.34% of all cancers with non-small cell lung carcinoma, melanoma, colorectal adenocarcinoma, uterine corpus neoplasm, and ovarian neoplasm having the greatest prevalence of alterations [3].
The most common alterations in MECOM are MECOM Mutation (1.17%), MECOM Amplification (0.17%), MECOM G614Efs*30 (0.05%), MECOM E24K (0.02%), and MECOM P276L (0.01%) [3].
Clinical Trials
Significance of MECOM in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.